The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications

318Citations
Citations of this article
121Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome. © 2005 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Podar, K., & Anderson, K. C. (2005, February 15). The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2004-07-2909

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free